All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Chronic thromboembolic pulmonary hypertension (CTEPH) constitutes Group 4 of the Dana Point classification of pulmonary hypertension (PH) and is considered an uncommon sequel of acute pulmonary thromboembolism (PE). The cumulative incidences of CTEPH range between 1.5% and 5.1% of survived PE \[[@pone.0147396.ref001],[@pone.0147396.ref002],[@pone.0147396.ref003]\]. Why these patients who have survived an acute PE continue to develop CTEPH is largely unknown.

The characteristics of CTEPH is the presence of unresolved thromboemboli undergoing fibrotic organisation. Although CTEPH is understood as a thromboembolic disorder, neither classical plasmatic risk factors for venous thromboembolism nor defects in fibrinolysis are found to be associated with CTEPH \[[@pone.0147396.ref004]\]. And secondary remodeling processes are believed to occur in distal pulmonary vascular bed of CTEPH patients, which is histologically indistinguishable from idiopathic pulmonary arterial hypertension (PAH) \[[@pone.0147396.ref005]\]. The pathophysiological mechanism of PAH is, increasingly clear, that contributing factors (such as hypoxia, drugs, toxins, inflammation, etc.) involving the action of vasoconstrictive and remodeling processes on a background of genetic predisposition \[[@pone.0147396.ref006]\]. Genetic predisposition caused by heterogeneous germline mutation of the bone morphogenetic protein type Ⅱ receptor (BMPR2) gene (*BMPR2*) has been found to account for approximately 75% of patients with heritable PAH, and up to 25% of idiopathic PAH \[[@pone.0147396.ref007]\]. Other genes which have been reported to be involved in the PAH pathogenesis so far are: partners in the transforming growth factor (TGF)-β signaling pathway including activin receptor-like kinase type 1 gene (*ACVRL1*) \[[@pone.0147396.ref008]\], endoglin gene (*ENG*) \[[@pone.0147396.ref009]\], SMAD9 gene (*SMAD9*) \[[@pone.0147396.ref010]\], and genes coded for caveolin-1 (*CAV1*) \[[@pone.0147396.ref011]\], potassium channel subfamily K, member 3 (*KCNK3*) \[[@pone.0147396.ref012]\], cerebellin 2 (*CBLN2*) \[[@pone.0147396.ref013]\]. The inheritance pattern of PAH, which is highly variable and with incomplete expression, implies the existence of environmental modifiers with the capability of modulating disease susceptibility. Since CTEPH share similar histopathological vascular lesions to idiopathic PAH and hereditary PAH, we hypothesized that mutations in heritable or idiopathic PAH genes might be found in patients with CTEPH. And the initial PE event might play as a trigger for facilitating the development of CTEPH.

In the present study, we analyzed the genetic variations in CTEPH patients and patients recovered from PE but without PH to explore whether mutations in known PAH-causing genes played a role in the development of CTEPH.

Materials and Methods {#sec002}
=====================

Patients {#sec003}
--------

Forty-nine CTEPH patients and 17 PE without PH patients were tested of gene mutation for *BMPR2*, *ACVRL1*, *ENG*, *SMAD9*, *CAV1*, *KCNK3*, and *CBLN2*. All study subjects belonged to the Chinese Han population, and were among patients admitted to the Center for Pulmonary Vascular Diseases of Fuwai Hospital from Oct. 2012 to Mar. 2015. CTEPH was diagnosed as: (1) a mean pulmonary arterial pressure ≥ 25 mmHg with a pulmonary capillary wedge pressure ≤ 15 mmHg based on right heart catheterization; (2) ventilation/perfusion lung scan and/ or computed tomographic pulmonary angiogram, and pulmonary angiography confirmed chronic thromboembolic obstruction. Patients recovered from PE and without PH were defined as (1) normal presentation of echocardiography and computed tomographic pulmonary angiogram during at least 1-year follow-up; (2) undergoing at least 6 months of therapeutic anticoagulation. Detected point mutations were screened in 120 unrelated healthy Chinese individuals to determine polymorphisms. Before participation, all study subjects signed written information consent. The study was approved by the Human Ethics Committee of Fuwai Hospital and conformed to the 1975 Declaration of Helsinki.

Molecular studies {#sec004}
-----------------

Genomic DNA was extracted from whole blood with a standard phenol-chloroform protocol. Direct DNA sequencing were performed to detect point mutations and small insertions/ deletions within coding regions and the flanking intron sequences. PCR primers were designed to amplify the coding regions and the intron/exon boundaries of all candidate genes, e.g. *BMPR2*, *ACVRL1*, *ENG*, *SMAD9*, *CAV1*, *KCNK3*, and *CBLN2*. The sequences of each pair of primers and PCR conditions are displayed in [Table 1](#pone.0147396.t001){ref-type="table"}. The coding DNA sequence 1 of *CBLN2* could not amplified by PCR because of technical problem. PCR products were analyzed by using an ABI 3730 XL (Applied Biosystems, Carlsbad, CA, USA). All results were compared with the reference sequences of the known PAH-associated genes including *BMPR2* (GenBank accession no. NM_001204.6), *ACVRL1* (GenBank accession no. NM_000020.2), *ENG* (GenBank accession no. NM_000118.2), *SMAD9* (GenBank accession no. NM_001127217.2), *CAV1* (GenBank accession no. NM_001753.4), *KCNK3* (GenBank accession no. NM_002246.2), and *CBLN2* (GenBank accession no. NM_182511.3). The standard nomenclature recommended by the Human Genome Variation Society ([www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen)) was employed to number mutations. Frequencies of single nucleotide polymorphisms (SNPs) of all candidate genes were compared to those previously reported in the HapMap database (<http://hapmap.ncbi.nih.gov/index.html.en>).

10.1371/journal.pone.0147396.t001

###### The primer sequences used for PCR amplification of coding sequences of 7 pulmonary arterial hypertension-associated genes.

![](pone.0147396.t001){#pone.0147396.t001g}

  CDS                      Forward (5'-3')Reverse(5'-3')   Annealing T~m~ (°C)   Product length (bp)
  ------------------------ ------------------------------- --------------------- ---------------------
  *BMPR2*                                                                        
  CDS 1                    CACCGAAGCGAAACTTAAGG            55                    786
                           AAGGCGATTTCCCTGGAAG                                   
  CDS 2                    GTCATTCGGATAAGACAAA             55                    335
                           TTTAACATACTCCCATGTCC                                  
  CDS 3                    CCCCCCATGAAATGTCTTTG            55                    459
                           GCCTGGCTTCAACCTTGAAT                                  
  CDS 4                    AGGAGCACATCTACTTGGTGTTTT        58                    542
                           AGTGGCATGGAAAGGGGTAG                                  
  CDS 5                    CTCCCAGAATTTGGCTTTCA            55                    454
                           GTGCCTAGAATAGGCCTTGAC                                 
  CDS 6                    CTGGGTCTGGTAGGAGCTTCA           55                    532
                           CGAGGCTGGTCCTGAACTCT                                  
  CDS 7                    CCTTTCCATCCCTTCCTCTC            58                    494
                           CGTGGGAAAGCTCTTTCTGT                                  
  CDS 8                    GAGTTGAAATTCCGATTTCTCTT         58                    463
                           CCAAGCTGGTCTCGAACTCT                                  
  CDS 9                    TCAGGAAGGGCATTTTATAGGT          55                    486
                           TGCATCCTGCTGCTAATAATGT                                
  CDS 10                   ATGTGCCTGAAGGGGATGAA            58                    396
                           TTGTGGCATTAGGCAACTCC                                  
  CDS 11                   TCCGTAATCCTTGAAGCCTAA           55                    525
                           GCAGATTTCATCTTGCACTTGT                                
  CDS 12A                  CATTTTTCAGTAGGCTTAATTCAC        55                    792
  CTGCTGTCCAGTTGCTTCTAC                                                          
  CDS 12B                  CAGGACTCACGCCAAGTACTG           55                    718
                           CGGGTGTCCTCACCAATAAAC                                 
  CDS 12C                  GGCAGCAAGCACAAATCAAA            55                    684
                           CGCCTCAAATGGATCATTTAC                                 
  CDS 13                   TGTCTGGCATTATGAATTTCAAG         55                    747
                           CCTTAAGAAACTGGTCCAAACTG                               
  *ENG*                                                                          
  CDS 1                    CGGTCATACCACAGCCTTCAT           60                    684
                           CGTCGCTGCACAGCATTCT                                   
  CDS 2                    GCCGTTAGCTCATGTCAAGTC           55                    305
                           TGCCTTGGAGCTTCCTCTG                                   
  CDS 3                    ACAGAGCAGGCAGGGAGAGT            58                    336
                           AGACCCTGACCCACAGAGATG                                 
  CDS 4                    ATTCTCAGCTCCGGCCTCT             60                    414
                           GAACTGTGGCACAGCGTGTC                                  
  CDS 5                    ATCTTTGGCTGTGGGTGAGG            55                    401
                           GGTGGGGCTTTATAAGGGAC                                  
  CDS 6                    ACCTGGCCAGGTAAGAGTGC            58                    387
                           CACTCCTGCTGCGTCTTCTG                                  
  CDS 7                    CGAGCTGAGCTGAAGGACAA            55                    428
  ACAGAGGTGCTTCACCAACAGT                                                         
  CDS 8                    CAGCATTGTGGCATCCTTCG            60                    861
                           GCCAGCTCAGGGAGCATTTA                                  
  CDS 9                    GGGGAATGGCTGTGACTT              55                    405
                           GGAGACTAAGCCAACCAATG                                  
  CDS 10                   CCATTGGTTGGCTTAGTCTC            55                    301
                           CTGCTCCGGTCATACAGAAG                                  
  CDS 11                   AGAGTCAGGCAACTCCACAG            58                    384
                           CCTGAGCAATGCCTTCTCT                                   
  CDS 12                   GACTCAGGGGTGGGAACTC             55                    496
                           GGCCACATGCCTGATTAAG                                   
  CDS 13                   AGCTACGAAGCGGTGGAGAT            55                    289
                           CCCTTGCCATGTGCTATGTG                                  
  CDS 14A                  AGCCCAGTGAAGCCTCTGA             60                    466
                           TGGCAAGTGGTCTGTCTCCT                                  
  CDS 14B                  CAGCCACTGGCTTGGAACA             60                    646
                           CCTGGATGCTGCTACTGTTCA                                 
  *ACVRL1*                                                                       
  CDS 1                    CAGCGGCTGTCACACTTCAT            58                    249
                           CACTCTCCAGTCAAGCTCCTACA                               
  CDS 2                    TTCTGAGGGAAGGATGACTGA           58                    560
  CAGACCACTCTGCCAGTTAGAT                                                         
  CDS 3                    GGATCTAACTGGCAGAGTGGT           58                    386
                           CCACCGGCTCTAATCTCTG                                   
  CDS 4                    GAGTGAGGAGCTTGCAGTGAC           55                    295
                           ACCGCCTGTGATTCCAGTAG                                  
  CDS 5                    AGCGCAGCATCAAGATGG              55                    309
                           AATGTCTGGAGGTCTGCAAACT                                
  CDS 6                    CCACCCCCAGACCTAGCTTA            55                    545
                           TCTTGCGGAGGAGAACTGAA                                  
  CDS 7                    CCAGGTCTGCTCTGTGAAGTG           55                    520
                           CTGGCTCCACAGGCTGATT                                   
  CDS 8                    CTCAGGGGTAGCGTGTCCA             58                    344
                           AGGCCTCAGACACAAGTTCC                                  
  CDS 9                    GGCCATCCTCCTCATCTTCT            58                    582
                           CTGGCTTGGCACTCTGACTC                                  
  *KCNK3*                                                                        
  CDS 1                    GACGATGAAGCGGCAGAAC             55                    433
                           GCTGAACTCGGGTTTCTGC                                   
  CDS 2A                   TGGACCCAGACCCACAAG              55                    575
                           TCATGAAGCGCAGCACC                                     
  CDS 2B                   CAGTACGTGGCCTTCAGCTT            55                    684
  AGCAGGCACAGTCGGAGAT                                                            
  *CBLN2*                                                                        
  CDS 2                    GGCAGTGTTGCTGGTTATCC            55                    293
                           AGCCTCAGAGACCAGGTGAA                                  
  CDS 3                    CAAGCTGCCGGTTCTCTATT            55                    622
                           GAAGGAGGCAGTGCTGAAGTTA                                
  *SMAD 9*                                                                       
  CDS 1                    TGTGGCCTCTTATGCACTCC            55                    614
                           TGATTGGACAGCTGCCTCAT                                  
  CDS 2                    GTTCCCAAGGGGAAAAACAG            55                    559
                           TCCAGGGTAACTGCTTCAAAAT                                
  CDS 3                    AGGCTCTCAGAACAACCAGTTT          55                    423
                           CAAAACAGCAGGCCAGTACA                                  
  CDS 4                    GAGCGGCATGCTTGGTCTT             55                    515
                           TGCTTTCCCCAGTGGTAATG                                  
  CDS 5                    TAAGCGGCATTTAGGTCACAC           58                    512
                           TGTCTATCAGAATTGACCGCACA                               
  CDS 6                    CAGGAAGGTAGAGGCCATGTT           58                    731
                           CTGTAGGGGTTTCACTGCTTTG                                
  *CAV1*                                                                         
  CDS 1                    TCCACCCCTGCTGAGATGAT            55                    498
  GGCAGCAGTCGGGATATTTG                                                           
  CDS 2                    GTCGGAGCGGTTAGTTCGAT            55                    494
                           GTAACGTTTCTGCCGACTGC                                  
  CDS 3                    TGTGTTCCCAAGTTCCAAGTG           55                    780
                           AGCCAATAAAGCGATGGTTGAT                                

CDS: coding DNA sequence.

Thirty CTEPH patients and 14 PE without PH patients who no mutation has been detected by direct DNA sequencing undergone multiple ligation probe amplification (MLPA) analysis for *BMPR2*, *ACVRL1*, and *ENG* by using SALSA MLPA1P093 HHT probe mix kit (MRC-Holland, Amsterdam, the Netherlands). Samples were analyzed using an ABI 3730 Genetic Analyzer, and the results were visualized by the Coffalyser software (MRC-Holland).

Statistical analysis {#sec005}
--------------------

The demographic and clinical characteristics of different groups were compared using the student's t tests or the Mann-Whitney U test for continuous variables, and chi-square tests for categorical variables. Differences in the frequencies of targeted gene mutations and the distribution of SNPs between the CTEPH patients and PE without PH patients were evaluated using the Fisher's exact test. By using the chi-square test, we tested whether the genotype distributions for the studied SNPs were in the Hardy-Weinberg equilibrium. A p value \<0.05 were considered as statistical significant. All statistical analyses were performed using the Statistical Package for Social Science (SPSS) 16.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results {#sec006}
=======

Clinical characteristics of the study population {#sec007}
------------------------------------------------

The clinical characteristics of the CTEPH patients and PE without PH patients were displayed on [Table 2](#pone.0147396.t002){ref-type="table"}. The mean±SD age was 51±16 years for CTEPH patients, and 53±18 years for PE without PH patients. Forty-nine percent of CTEPH patients and 41% of PE without PH patients were female. The levels of N-terminal pro-brain natriuretic peptide were significantly higher in CTEPH patients than that in PE without PH patients. While levels of oxygen saturation were significantly lower in CTEPH patients compared with the PE without PH patients.

10.1371/journal.pone.0147396.t002

###### Clinical characteristics of study subjects.
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                           CTEPH(n = 49)   PE without PH(n = 17)   p value
  ------------------------ --------------- ----------------------- ---------
  Age (years)              51±16           53±18                   0.646
  Female (%)               24 (49)         7 (41)                  0.779
  BMI (kg/m^2^)            22.74±3.26      26.13±2.74              \<0.001
  NT-proBNP (pg/ml)        2408.6±1909.7   315.6±223.5             \<0.001
  SaO~2~ (%)               91.14±4.43      95.11±3.25              0.001
  mPAP (mmHg)              60±14                                   
  PVR (Wood units)         14.16±3.48                              
  CI (L/min.m^2^)          2.53±0.48                               
  Previous history of PE   14 (29)                                 
  Distal (%)               14 (29)                                 

CTEPH: chronic thromboembolic pulmonary hypertension; PE: pulmonary embolism; PH: pulmonary hypertension; BMI: body mass index; NT-proBNP: N-terminal pro-brain natriuretic peptide; SaO~2:~ oxygen saturation; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; CI: cardiac index.

Mutation rate and distribution {#sec008}
------------------------------

Sixty-six (n = 66) sequences were included for analysis. These sequences were obtained from patients with CTEPH (n = 49) and patients recovered from PE and without PH (n = 17). A total of 40 mutations were identified, including 31 point mutations and 9 large size rearrangements ([Table 3](#pone.0147396.t003){ref-type="table"}). Among them, 5 mutations were synonymous (3 in CTEPH patients, 2 in PE without PH patients).

10.1371/journal.pone.0147396.t003

###### categories of gene mutations in CTEPH patients and PE without PH patients.
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  Patient         Point mutation   large size rearrangement   Total       
  --------------- ---------------- -------------------------- ------- --- ----
  CTEPH           3                16                         9       5   33
  PE without PH   2                1                          0       4   7
  Total           5                17                         9       9   40

CTEPH: chronic thromboembolic pulmonary hypertension; PE: pulmonary embolism; PAH: pulmonary arterial hypertension; VUS: variant of unknown significance.

Point mutation analysis is summarized in [Table 4](#pone.0147396.t004){ref-type="table"}. Portions of these transitions were subsequently analyzed in 120 unrelated healthy Chinese individuals (Table A in [S1 File](#pone.0147396.s001){ref-type="supplementary-material"}). PolyPhen-2 was employed to predict the effect on protein function. Thirteen mutations were predicted to be probably damaging, 2 mutation was predicted to be possibly damaging, and 2 mutations were predicted to be benign. Three patients had multiple point mutations.

10.1371/journal.pone.0147396.t004

###### Gene mutations in Chinese CTEPH patients and PE without PH patients.
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  Patientsnumber   Group           Gene       Location   Nucleotide change                                 Amino acid change   Mutation type
  ---------------- --------------- ---------- ---------- ------------------------------------------------- ------------------- ---------------
  54               CTEPH           *BMPR2*    5'-UTR     c.-93A\>G                                         p.?                 VUS
  183              PE without PH              Exon3      c.292G\>A                                         Glu98Lys            Missense
  101              CTEPH                      Exon11     c.1569T\>C                                        Thr523Thr           Synonymous
  281              CTEPH                      Exon12     c.1739G\>T[\*](#t004fn002){ref-type="table-fn"}   Gly580Val           Missense
  198              CTEPH                      Exon12     c.2030T\>A[\*](#t004fn002){ref-type="table-fn"}   Let677His           Missense
  275              CTEPH                      Exon12     c.2006A\>G[\*](#t004fn002){ref-type="table-fn"}   Asp669Gly           Missense
  285              CTEPH                      Exon12     c.2325C\>A                                        Ser775Arg           Missense
  248              CTEPH                      Exon12     c.2357C\>G[\*](#t004fn002){ref-type="table-fn"}   Thr786Ser           Missense
  121              CTEPH                      Exon12     c.2663T\>G                                        Val888Gly           Missense
  198              CTEPH           *ENG*      Intron13   c.111+62A\>G                                      p.?                 VUS
  77               CTEPH                      3'-UTR     c.124+277A\>G                                     p.?                 VUS
  248              CTEPH           *ACVRL1*   Exon5      c.583C\>T[\*](#t004fn002){ref-type="table-fn"}    Gln195Trp           Missense
  198              CTEPH                      Exon8      c.1196G\>T[\*](#t004fn002){ref-type="table-fn"}   Trp399Leu           Missense
  2                CTEPH                      Exon10     c.1450C\>G[\*](#t004fn002){ref-type="table-fn"}   Arg484Gly           Missense
  191              CTEPH                      Exon10     c.1450C\>G[\*](#t004fn002){ref-type="table-fn"}   Arg484Gly           Missense
  263              CTEPH                      Exon10     c.1450C\>G[\*](#t004fn002){ref-type="table-fn"}   Arg484Gly           Missense
  285              CTEPH                      Exon10     c.1450C\>G[\*](#t004fn002){ref-type="table-fn"}   Arg484Gly           Missense
  274              CTEPH           *KCNK3*    Exon1      c.92C\>A[\*](#t004fn002){ref-type="table-fn"}     Ser31Trp            Missense
  117              PE without PH              Exon2      c.414C\>T                                         Tyr138Tyr           Synonymous
  262              CTEPH           *CBLN2*    3'-UTR     c.200+108G\>C                                     ?                   VUS
  285              CTEPH                      3'-UTR     c.200+630T\>C                                     ?                   VUS
  211              PE without PH              Exon5      c.648T\>C                                         Phe216Phe           Synonymous
  285              CTEPH           *SMAD9*    5'-UTR     c.-98C\>T                                         ?                   VUS
  278              CTEPH                      Exon2      c.260T\>A[\*](#t004fn002){ref-type="table-fn"}    Leu87Gln            Missense
  285              CTEPH                      Exon3      c.521A\>G[\*](#t004fn002){ref-type="table-fn"}    Asn174Ser           Missense
  235              CTEPH           *CAV1*     5'-UTR     c.-106A\>G                                        p.?                 VUS
  235              CTEPH                      5'-UTR     c.-17T\>C                                         p.?                 VUS
  287              CTEPH                      Exon2      c.76A\>G                                          Lys26Glu            Missense
  263              CTEPH                      Exon3      c.387A\>G                                         Ala129ALa           Synonymous
  191              CTEPH                      Exon3      c.462C\>T                                         Thr154Thr           Synonymous
  124              CTEPH                      3'-UTR     c.341+274A\>T                                     p.?                 VUS

CTEPH: chronic thromboembolic pulmonary hypertension; PE: pulmonary embolism; PH: pulmonary hypertension; UTR: untranslated region; VUS: variant of unknown significance. Numbering is based on +1 as A of the ATG initiation codon.

\*: missense mutation predicted to be probably damaging by Polyphen-2 software.

The large size rearrangement analysis is summarized in [Table 5](#pone.0147396.t005){ref-type="table"}. Three patients had more than one large size rearrangements.

10.1371/journal.pone.0147396.t005

###### Large size rearrangement identified in CTEPH patients and PE without PH patients.
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  Identification number   Diagnosis       Gene              Rearrangement
  ----------------------- --------------- ----------------- -----------------------
  270                     CTEPH           BMPR2 exon 1      c.1-?\_c.76+?del
                                          ENG exon 6        c.690-?\_c.816+?del
                                          ENG exon 11--14   c.1312-?\_c.1977+?del
  282                     CTEPH           BMPR2 exon 1      c.1-?\_c.76+?del
                                          ENG exon 12       c.1429-?\_c.1686+?del
  187                     PE without PH   ENG exon 14       c.1742-?\_c.1977+?dup
  603                     PE without PH   ENG exon 5        C.524-?\_c.689+?dup
                                          ENG exon 8        c.992-?\_1134+?dup
                                          ENG exon 14       c.1742-?\_c.1977+?dup

Abbreviations are in accord with nomenclature guidelines as recommended by the Human Genome Variation Society. CTEPH: chronic thromboembolic pulmonary hypertension; PE: pulmonary embolism; PH: pulmonary hypertension; del: deletion; dup: duplication; c.: coding DNA where nucleotide 1 is the A of the ATG translation initiation codon.

The nonsynonymous mutation rate in CTEPH patients is significantly higher than that in PE without PH patients (25 out of 49 (51%) CTEPH patients *vs*. 3 out of 17 PE without PH patients (18%); p = 0.022). The mutation rate for individual gene was displayed on [Fig 1](#pone.0147396.g001){ref-type="fig"}.

![Distribution of nonsynonymous mutations of 7 pulmonary arterial hypertension-causing genes in chronic thromboembolic pulmonary hypertension patients and patients recovered from pulmonary embolism and without pulmonary hypertension.](pone.0147396.g001){#pone.0147396.g001}

Polymorphisms {#sec009}
-------------

Twelve SNPs which already recorded in the public dbSNP database were detected among all the 66 patients ([Table 6](#pone.0147396.t006){ref-type="table"}). Four single nucleotide changes were considered to be polymorphisms because they were also found in control individuals ([Table 6](#pone.0147396.t006){ref-type="table"}). Genotype distributions of the studied SNPs were all in Hardy-Weinberg equilibrium. We compared the genotype and allele frequencies of these SNPs between the CTEPH patients and the PE without PH patients, and found out that the allele of SNP rs3739817 and SNP rs55805125 were significantly correlated with CTEPH.

10.1371/journal.pone.0147396.t006

###### Outline of SNPs.
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  SNPs                 Genotype           P value          Allele     P value     OR                                              
  -------------------- ------------------ ---------------- ---------- ----------- ------------------ ---------------- ----------- --------------------
  rs140683387          A/A                A/T              T/T                    A                  T                1.000       \-
  CTEPH                48(0.98)           1(0.02)          0(0)       1.000       97(0.99)           1(0.01)                      
  PE without PH        17(1.0)            0(0)             0(0)                   34(1.00)           0(0)                         
  rs369291114          C/C                C/T              T/T                    C                  T                1.000       \-
  CTEPH                48(0.98)           1(0.02)          0(0)       1.000       97(0.99)           1(0.01)                      
  PE without PH        17(1.0)            0(0)             0(0)                   34(1.00)           0(0)                         
  rs1061157            G/G                G/A              A/A                    G                  A                0.446       2.776(0.36--21.39)
  CTEPH                41(0.84)           8(0.16)          0(0)       0.427       90(0.92)           8(0.08)                      
  PE without PH        16(0.94)           1(0.06)          0(0)                   33(0.97)           1(0.03)                      
  rs148475405          C/C                C/T              T/T                    C                  T                0.450       0.347(0.02--5.40)
  CTEPH                48(0.98)           1(0.02)          0(0)       0.452       97(0.99)           1(0.01)                      
  PE without PH        16(0.94)           1(0.06)          0(0)                   33(0.97)           1(0.03)                      
  rs11545664           G/G                G/A              A/A                    G                  A                1.000       1.041(0.11--9.67)
  CTEPHPE without PH   46(0.94)16(0.94)   3(0.06)1(0.06)   0(0)0(0)   1.000       95(0.97)33(0.97)   3(0.03)1(0.03)               
  rs1800956            G/G                G/C              C/C                    G                  C                1.000       0.925(0.26--3.29)
  CTEPH                43(0.88)           4(0.08)          2(0.04)    0.404       90(0.92)           8(0.08)                      
  PE without PH        14(0.82)           3(0.18)          0(0)                   31(0.91)           3(0.09)                      
  rs3739817            C/C                C/T              T/T                    C                  T                **0.038**   0.173(0.03--0.91)
  CTEPH                48(0.98)           0(0)             1(0.02)    **0.003**   96(0.98)           2(0.02)                      
  PE without PH        13(0.76)           4(0.24)          0(0)                   30(0.88)           4(0.12)                      
  rs55805125           C/C                C/T              T/T                    C                  T                **0.016**   0.087(0.01--0.75)
  CTEPH                48(0.98)           1(0.02)          0(0)       **0.014**   97(0.99)           1(0.01)                      
  PE without PH        13(0.76)           4(0.24)          0(0)                   30(0.88)           4(0.12)                      
  rs199874575          C/C                C/T              T/T                    C                  T                0.300       \-
  CTEPH                49(1.00)           0(0)             0(0)       0.258       98(1.00)           0(0)                         
  PE without PH        16(0.94)           1(0.06)          0(0)                   33(0.98)           1(0.02)                      
  rs368057934          C/C                C/T              T/T                    C                  T                1.000       \-
  CTEPH                48(0.98)           1(0.02)          0(0)       1.000       97(0.99)           1(0.01)                      
  PE without PH        17(1.00)           0(0)             0(0)                   34(1.00)           0(0)                         
  rs549923058CTEPH     G/G48(0.98)        G/A1(0.02)       A/A0(0)    1.000       G97(0.99)          A1(0.01)                     
  PE without PH        17(1.00)           0(0)             0(0)                   34(1.00)           0(0)             1.000       \-
  rs79733377           C/C                C/A              A/A                    C                  A                0.450       0.347(0.02--5.40)
  CTEPH                48(0.98)           1(0.02)          0(0)       0.452       97(0.99)           1(0.01)                      
  PE without PH        16(0.94)           1(0.06)          0(0)                   33(0.97)           1(0.03)                      
  *ENG* c.-59C\>A      C/C                C/A              A/A                    C                  A                1.000       \-
  CTEPH                48(0.98)           1(0.02)          0(0)       1.000       97(0.99)           1(0.01)                      
  PE without PH        17(1.00)           0(0)             0(0)                   34(1.00)           0(0)                         
  CBLN2 exon5                                                                                                                     
  c.527A\>C            C/C                C/A              A/A                    C                  A                0.230       1.388(0.84--2.28)
  CTEPH                12(0.24)           26(0.53)         11(0.23)   0.365       50(0.51)           48(0.49)                     
  PE without PH        7(0.41)            8(0.47)          2(0.12)                22(0.65)           12(0.35)                     
  CBLN2 exon5                                                                                                                     
  c.628T\>C            T/T                T/C              C/C                    T                  C                1.000       1.388(0.31--6.22)
  CTEPH                2(0.04)            4(0.08)          43(0.88)   0.704       8(0.08)            90(0.92)                     
  PE without PH        0(0)               2(0.12)          15(0.88)               2(0.06)            32(0.94)                     
  SMAD9 exon3                                                                                                                     
  c.487G\>C            G/G                G/C              C/C                    G                  C                1.000       \-
  CTEPH                48(0.98)           1(0.02)          0(0)       1.000       97(0.08)           1(0.92)                      
  PE without PH        17(0)              0(0)             0(0)                   34(1.00)           0(0)                         

SNP: single nucleotide polymorphism; CTEPH: chronic thromboembolic pulmonary hypertension; PE: pulmonary embolism; PAH: pulmonary arterial hypertension.

Clinical characteristics of CTEPH patients in mutation carriers and noncarriers {#sec010}
-------------------------------------------------------------------------------

There is no significance of gender, age, previous PE history, and hemodynamic parameters between the mutation carriers and noncarriers CTEPH patients. However, BMI in mutation carriers are lower than the noncarriers ([Table 7](#pone.0147396.t007){ref-type="table"}). Detailed information for each patient was displayed on Table B in [S1 File](#pone.0147396.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0147396.t007

###### Comparison of clinical characteristics of CTEPH patients in nonsynonymous mutation carriers and noncarriers.

![](pone.0147396.t007){#pone.0147396.t007g}

  Variable                     Mutation carrier(n = 19)   Noncarrier(n = 30)   p value
  ---------------------------- -------------------------- -------------------- ---------
  Age (years)                  51±15                      51±17                0.918
  Female (%)                   9 (53)                     14 (47)              0.684
  BMI (kg/m^2^)                21.55±2.53                 23.78±3.56           0.022
  NT-proBNP (pg/ml)            2311.0±2245.8              2474.9±1685.2        0.776
  SaO~2~ (%)                   92.23±3.44                 90.53±4.80           0.188
  mPAP (mmHg)                  59±16                      61±12                0.640
  PVR (Wood units)             13.29±2.64                 14.09±3.04           0.345
  CI (L/min.m^2^)              2.68±0.43                  2.52±0.44            0.239
  Previous history of PE (%)   5 (26)                     9 (30)               0.781
  Distal (%)                   5 (26)                     8 (27)               0.978

CTEPH: chronic thromboembolic pulmonary hypertension; BMI: body mass index; NT-proBNP: N-terminal pro-brain natriuretic peptide; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; CI: cardiac index; PE: pulmonary thromboembolism.

Discussion {#sec011}
==========

The present study is the first to investigate the association between the genotype of PAH-causing genes and the development of CTEPH. We screened 7 known PAH-causing genes in 49 Chinese CTEPH patients and 17 PE without PH patients. We found that CTEPH patients had a higher frequency of mutations in PAH-causing genes compared with PE without PH patients. And we also found two previously identified SNPs (rs3739817 and rs55805125) were significantly correlated with CTEPH.

The underlying mechanism of CTEPH is largely unknown. Since the characterization of CTEPH is the presence of unresolved thromboemboli undergoing fibrotic organization and secondary remodeling processes of the pulmonary vascular bed \[[@pone.0147396.ref004]\], previous researches have focused on the imbalance between thrombosis and fibrinolysis. However, no correlation has been found between CTEPH and the classical thromboembolic risk factors such as the deficiency of antithrombin, protein C and protein S, the gene mutation of prothrombin, factor V Leiden, and hyperhomocysteinaemia \[[@pone.0147396.ref014]\]. In one research, the investigators found that fibrin derived from CTEPH patients was resistant to lysis compared with the healthy controls \[[@pone.0147396.ref015]\]. But a recent study showed that fibrin resistance to lysis occurred in PAH other than CTEPH and, to a smaller extent, in prior PE without PH patients \[[@pone.0147396.ref016]\]. These findings imply that CTEPH might develop in a more insidious way other than abnormal coagulation and fibrinolysis, especially in those patients who develop CTEPH after the first episode of PE. This assumption seems plausible if we take it into consideration that only a small part of PE patients developed CTEPH, though the percentage of patients with residual pulmonary thrombi was as high as 52% after 11 months of PE diagnosis \[[@pone.0147396.ref017]\]. In a series of histopathologic studies in CTEPH patients, researchers reported that there were not only the thrombi obstructions in large vessels, but lesions similar to PH including plexogenic lesions were observed under microscopy \[[@pone.0147396.ref018],[@pone.0147396.ref019],[@pone.0147396.ref020]\]. And these typical plexogenic lesions distributed in both of the no-flow lung tissues and normal-flow lung tissues \[[@pone.0147396.ref020]\]. These findings suggest that CTEPH might develop in a mechanism similar to PAH.

It's acknowledged that gene mutation play a pivotal role in PAH. The inheritance pattern is complex due to the incomplete penetrance. The penetrance is influenced by environmental factors such as hormone, appetite-suppressant drugs, concurrent inflammation, reactive oxygen species formation \[[@pone.0147396.ref007]\]. So we hypothesized that genetic predisposition for PAH might exist in some CTEPH patients, and the PE event might act as a second genetic hit within the pulmonary vasculature to promote the mutation gene expression, which lead to endothelial cell proliferation and finally development of CTEPH. *BMPR2* was identified as the first PAH-causing gene in 2000 by two teams of investigators. After that, *AVCRL1* (or *ALK1*) and *ENG* were reported as the PAH-causing genes in 2001 and 2004 respectively \[[@pone.0147396.ref008],[@pone.0147396.ref009]\]. These three genes are all belong to the transforming growth factor-beta (TGF-β) receptor superfamily. The TGF-β superfamily comprises a large series of cytokine growth factors that controls a host of cellular functions, including proliferation, migration, differentiation, apoptosis, and extracellular matrix secretion and deposition. In 2009, several teams identified mutation in *SMAD9*, another member of TGF-β superfamily, in patients with PAH \[[@pone.0147396.ref007]\]. In 2012, a mutation in *CAV1* (codes for caveolin-1, a membrane protein of caveolae abundant in the endothelium and other cells of the lung) was identified in hereditary PAH patients \[[@pone.0147396.ref011]\]. In 2013, two novel genes, *KCNK3* (the gene encoding potassium channel subfamily K, member 3) and *CBLN2* (codes for cerebellin 2) were detected in hereditary and idiopathic PAH patients \[[@pone.0147396.ref012],[@pone.0147396.ref013]\].

In the present study, we identified 25 nonsynonymous point mutations and 5 large size rearrangements in 19 out of 49 CTEPH patients, including 9 mutations in *BMPR2*, 5 mutations in *ENG*, 6 mutations in *ACVRL1*, 1 mutation in *KCNK3*, 2 mutations in *CBLN2*, 3 mutations in *SMAD9*, and 4 mutations in *CAV1*. While in 17 PE without PH patients, 1 patient with *BMPR2* point mutation and 2 patients with 4 large size rearrangements of *ENG* were identified. *BMPR2* is the most studied PAH-causing gene. It comprises 13 exons and harbors four distinct functional domains. Over 300 *BMPR2* unique mutations have been reported so far \[[@pone.0147396.ref021]\], which distribute in all 13 exons. Six missense mutation of *BMPR2* identified in CTEPH patients in the present study were confined to exon 12, which codes for the cytoplasmic tail. Four of these 6 missense mutations were predicted to be probably damaging by Polyphen-2 software. Surprisingly, we found one mutation in exon 3 in PE without PH patients. Exon 3 codes for an extracellular binding ligand. But the mutation was predicted to be possible damaging by Polyphen-2 software with a score of 0.515. A thorough history and clinical examination did not reveal any sign for PH in this patient or his family. All 6 missense mutations in *ACVRL1* detected in CTEPH were predicted to be probably damaging with scores of 1.0. The mutations were located in exon 5, 8, 10. *ACVRL1* exon 5 codes for the glycine- serine domain, and exons 6--10 code for the kinase domain, all are critical for signaling activity of *ACVRL1*. Four CTEPH patients had the same point mutation in *ACVRL1* exon 10 (c.1450C\>G), a variant which had been observed cosegregated with PH in a hereditary hemorrhagic telangiectasia kindred \[[@pone.0147396.ref008]\]. And histologic assessment had demonstrated that the affected patients had characteristic features of end-stage plexogenic PH similar to those seen in patients with idopathic PH.

The SMAD signal pathway is most strongly associated with driving the differentiation state in development. And the *SMAD9* variants are more convincingly associated with PAH among all *SMADs* according to previous researches \[[@pone.0147396.ref007]\]. In the present study, we found 2 *SMAD9* missense mutations, which were predicted to be probably damaging. *KCNK3* encodes an pH-sensitive potassium channel protein that contains two pore-forming P domains. *KCNK3* channels are major contributors to the resting potential in human pulmonary-artery smooth muscle cells. Gurney AM, et al \[[@pone.0147396.ref022]\] suggested that the pH-sensitive channels could be responsible for the modulatory effects of pH on hypoxic pulmonary vasoconstriction. In the present study, we found a missense mutation in *KCNK3* exon 1 in one CTEPH patient. The mutation was predicted to be probably damaging with a score of 1.0. It is plausible that the *KCNK3* mutation might play an important role in CTEPH after the initial PE-induced hypoxia in pulmonary vasculature. *CAV1* encodes caveolin-1, which is the predominant member of three proteins (caveolin-1, caveolin-2, and caveolin-3) that coat the flask-like invaginations of the plasma membrane known as caveolae. Signaling cascades relevant to PAH such as the TGF-β superfamily, nitric oxide pathway, and G-protein coupled receptors rely heavily on proper caveolar function \[[@pone.0147396.ref023]\]. We identified one missense mutation in *CAV1* exon2, which was predicted to be possible damaging.

In addition, we found mutations in untranslated regions and introns of *BMPR2*, *ENG*, *SMAD9*, *CAV1*, and *CBLN2* (encodes cerebellin 2, which highly expressed in lungs of PAH patients). And we found a significant association between the genotypes of 2 SNPs rs3739817 (*ENG* exon8) and rs55805125 (*ACVRL1* exon 7) with CTEPH. Although there was no encoding amino acid changes resulting from these mutations and polymorphisms, they may modify gene expression, or cause aberrant pre-mRNA splicing due to alternations in sequences recognized by various splicing factors.

Lack of functional analyses of these mutations is the main limitation of the present study. But previous study provided a convincing evidence for the association between one specific mutation in *ACVRL1* exon 10 with PH. Besides, the relatively small sample of patients hindered a thorough mapping of PAH-causing genes variants in CTEPH patients.

Conclusions {#sec012}
===========

Based on direct sequencing and MLPA method, we identified 25 nonsynonymous point mutations, 5 large size rearrangements, and 2 CTEPH associated SNPs of 7 PAH-causing genes (*BMPR2*, *ACVRL1*, *ENG*, *SMAD9*, *CAV1*, *KCNK3*, *and CBLN2*) out of 49 CTEPH patients. Among them, one specific mutation in *ACVRL1* exon 10 shared by 4 CTEPH patients had been approved to be associated with PH in a previous study. The high frequency of mutations of PAH-causing genes might be associated with CTEPH in Chinese population.

Supporting Information {#sec013}
======================

###### Gene mutaion in 120 healthy controls (Table A).Clinical characteristics of the CTEPH subjects (Table B).
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Click here for additional data file.
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BMPR2

:   bone morphogenetic protein type Ⅱ receptor

CTEPH

:   chronic thromboembolic pulmonary hypertension

MLPA

:   multiple ligation probe amplification
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:   pulmonary arterial hypertension
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:   pulmonary thromboembolism
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:   pulmonary hypertension

SNP
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